Open AccessEffects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
Author(s) -
Nelson B. Watts,
John P. Bilezikian,
Keith Usiskin,
Robert Edwards,
Mehul Desai,
Gordon Law,
Gary Meininger
Publication year - 2015
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2015-3167
Subject(s) - canagliflozin , medicine , type 2 diabetes mellitus , diabetes mellitus , type 2 diabetes , endocrinology
Canagliflozin is a sodium glucose cotransporter 2 inhibitor developed to treat type 2 diabetes mellitus (T2DM).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom